Switch theme
Sign up to access all valuation multiples
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
1949
17.3K+
LTM Revenue $1.0B
LTM EBITDA $202M
$4.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ipca Laboratories has a last 12-month revenue of $1.0B and a last 12-month EBITDA of $202M.
In the most recent fiscal year, Ipca Laboratories achieved revenue of $885M and an EBITDA of $155M.
Ipca Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ipca Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $721M | $885M | XXX | XXX | XXX |
| Gross Profit | $425M | $441M | XXX | XXX | XXX |
| Gross Margin | 59% | 50% | XXX | XXX | XXX |
| EBITDA | $122M | $155M | XXX | XXX | XXX |
| EBITDA Margin | 17% | 18% | XXX | XXX | XXX |
| Net Profit | $103M | $54.7M | XXX | XXX | XXX |
| Net Margin | 14% | 6% | XXX | XXX | XXX |
| Net Debt | $59.9M | $23.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ipca Laboratories's stock price is INR 1332 (or $15).
Ipca Laboratories has current market cap of INR 338B (or $3.9B), and EV of INR 340B (or $4.0B).
See Ipca Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0B | $3.9B | XXX | XXX | XXX | XXX | $0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ipca Laboratories has market cap of $3.9B and EV of $4.0B.
Ipca Laboratories's trades at 3.8x LTM EV/Revenue multiple, and 19.6x LTM EBITDA.
Analysts estimate Ipca Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ipca Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.0B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 20.9x | XXX | XXX | XXX |
| P/E | 41.1x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 44.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIpca Laboratories's NTM/LTM revenue growth is 13%
Ipca Laboratories's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $27K for the same period.
Over next 12 months, Ipca Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ipca Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ipca Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $27K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 52% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ipca Laboratories acquired XXX companies to date.
Last acquisition by Ipca Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Ipca Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ipca Laboratories founded? | Ipca Laboratories was founded in 1949. |
| Where is Ipca Laboratories headquartered? | Ipca Laboratories is headquartered in India. |
| How many employees does Ipca Laboratories have? | As of today, Ipca Laboratories has 17.3K+ employees. |
| Who is the CEO of Ipca Laboratories? | Ipca Laboratories's CEO is Mr. Pranay Godha. |
| Is Ipca Laboratories publicy listed? | Yes, Ipca Laboratories is a public company listed on BOM. |
| What is the stock symbol of Ipca Laboratories? | Ipca Laboratories trades under 524494 ticker. |
| When did Ipca Laboratories go public? | Ipca Laboratories went public in 1994. |
| Who are competitors of Ipca Laboratories? | Similar companies to Ipca Laboratories include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ipca Laboratories? | Ipca Laboratories's current market cap is $3.9B |
| What is the current revenue of Ipca Laboratories? | Ipca Laboratories's last 12-month revenue is $1.0B. |
| What is the current EBITDA of Ipca Laboratories? | Ipca Laboratories's last 12-month EBITDA is $202M. |
| What is the current EV/Revenue multiple of Ipca Laboratories? | Current revenue multiple of Ipca Laboratories is 3.8x. |
| What is the current EV/EBITDA multiple of Ipca Laboratories? | Current EBITDA multiple of Ipca Laboratories is 19.6x. |
| What is the current revenue growth of Ipca Laboratories? | Ipca Laboratories revenue growth between 2023 and 2024 was 23%. |
| Is Ipca Laboratories profitable? | Yes, Ipca Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
